Exelixis (EXEL)

• Market cap: $10.3B
• 1 day: -0.38%
• 5 days: -1.90%
• 1 month: -5.14%
• 3 months: 8.90%
• 6 months: 41.43%
• Year to date: 8.13%
• 1 year: 54.66%
• 5 years: 106.53%
• 10 years: 1,259.26%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

164% more first-time investments, than exits

New positions opened: 116 | Existing positions closed: 44

29% more capital invested

Capital invested by funds: $6.48B [Q3] → $8.34B (+$1.86B) [Q4]

18% more call options, than puts

Call options by funds: $58.6M | Put options by funds: $49.7M

14% more funds holding

Funds holding: 447 [Q3] → 511 (+64) [Q4]

14% more funds holding in top 10

Funds holding in top 10: 7 [Q3] → 8 (+1) [Q4]

5% more repeat investments, than reductions

Existing positions increased: 173 | Existing positions reduced: 164

0.04% more ownership

Funds ownership: 87.61% [Q3] → 87.65% (+0.04%) [Q4]

Research analyst outlook

14 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $29 21% downside
• Avg. target: $38 2% upside
• High target: $45 23% upside

14 analyst ratings

• positive: 9 64%
• neutral: 5 36%
• negative: 0 0%

HC Wainwright & Co. Robert Burns 20% 1-year accuracy 33 / 167 met price target	9% upside $40	Buy Reiterated	27 Mar 2025
RBC Capital Gregory Renza 32% 1-year accuracy 24 / 75 met price target	9% upside $40	Outperform Maintained	13 Mar 2025
Wells Fargo Derek Archila 41% 1-year accuracy 13 / 32 met price target	2% downside $36	Equal-Weight Downgraded	24 Feb 2025
Barclays Peter Lawson 10% 1-year accuracy 2 / 20 met price target	21% downside $29	Equal-Weight Maintained	13 Feb 2025
Citigroup David Lebowitz 32% 1-year accuracy 6 / 19 met price target	23% upside $45	Buy Maintained	12 Feb 2025